Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DDXSQ registration revoked:
https://www.sec.gov/litigation/opinions/2020/34-90586.pdf
DDXSQ SEC Suspension for severely delinquent Financials:
https://www.sec.gov/litigation/suspensions/2019/34-86759.pdf
Order:
https://www.sec.gov/litigation/suspensions/2019/34-86759-o.pdf
Admin. Proceeding:
https://www.sec.gov/litigation/admin/2019/34-86758.pdf
.031x.08
what a spread~!
DDXSQ
DDXS changed to DDXSQ, bankruptcy:
http://otce.finra.org/DLSymbolNameChanges
Could nor sell? Business Partner from May not interested.?
Thoughts on Why ?
Hawk
Diadexus, Inc. Previews First Quarter 2016 Financial Performance and Provides Business Update
SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 18, 2016) - Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced preliminary financial performance metrics for the first quarter ended March 31, 2016 and provided an update on its business.
"Our team's performance in executing our strategy to broaden and diversify our customer base as we launch our new PLAC® Activity Test is beginning to generate results and momentum in our business. During the first quarter, we have continued to contract with new customers as we launch our PLAC® Activity Test and we already are seeing volume growth as we deliver supply into regional and hospital labs, build awareness of the test's clinical utility and value, and drive demand for the product," said Lori Rafield, Ph.D., Chairman and Chief Executive Officer for Diadexus. "There is significant interest in this test from national labs, major hospital systems, regional reference labs, clinics and physician office labs as healthcare providers want FDA-cleared tests supported by extensive clinical data to inform decisions on how aggressively to manage patients who are at risk for coronary heart disease. Our commercial team has and will continue to execute on our strategy to broaden and diversify our base of customers and expect to deliver accelerating revenue growth through the launch of our PLAC® Activity Test."
Preliminary total revenues, comprised entirely of product sales, for the quarter ended March 31, 2016 were approximately $3.5 million, consistent with $3.5 million for the fourth quarter of 2015. Revenues reflect the loss of one of the Company's largest customers for the PLAC® ELISA Test, Atherotech, which filed for bankruptcy March 4, 2016, an increase in PLAC® ELISA Test volumes from other customers, and growth in PLAC® Activity Test volumes from new customers. Diadexus' second FDA-cleared test PLAC® Activity was launched actively in the fourth quarter of 2015.
Preliminary cash and cash equivalents at March 31, 2016 were approximately $6.3 million.
These preliminary results and balance are unaudited and may be subject to adjustment prior to Diadexus reporting financial results for the first quarter 2016, expected on or around April 28, 2016.
About Diadexus, Inc.
Diadexus, based in South San Francisco, California, is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. The Company pioneered the testing of Lp-PLA2, a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating its utility. Diadexus' products, The PLAC® Test ELISA Kit, first cleared by the FDA in 2003, and The PLAC® Test for Lp-PLA2 Activity, cleared in December 2014, are the only two FDA-cleared tests to measure Lp-PLA2.
The Company also has a pipeline of biomarkers for heart failure, proADM, proET-1 and proANP, each of which provide distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. To learn more about the PLAC® tests, please visit www.plactest.com, or visit the Company's website at www.diadexus.com.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, preliminary total revenues and cash and cash equivalents, statements related to our transition to a new business model and strategy and our ability to continue to execute our plans successfully, potential for revenue growth and expectations and guidance regarding our existing PLAC ELISA business, potential for pharmaceutical partner PLAC product collaborations, timing of regulatory submission and clinical and commercial need for our PLAC and ELISA tests. Forward-looking statements are based on current expectations and assumptions and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to us that could cause actual results to differ materially from those expressed in such forward-looking statements include the factors necessary to achieve our revenue and cash guidance; sales of our PLAC® products in the marketplace; our ability to maintain or grow revenues from existing and new customers, including hospitals, clinics and physician labs; viability of our leading customers; product pricing and demand with a concentrated customer base; the continued focus of regulatory agencies and payors on costs and our laboratory customer practices; our ability to continue to build our heart failure franchise; our ability to identify and build products with additional biomarkers; third party payors' acceptance of and reimbursement for the PLAC® tests; our ability to continue to manufacture the PLAC® tests to meet customer demand; the potential for success of and timing of when our development efforts may be completed; the adequacy of our intellectual property rights and our ability to maintain a proprietary position for our lead product; our limited revenue and cash resources; our significant corporate expenses, including real estate lease liabilities and expenses associated with being a public company; our ability to develop proADM for regulatory submission, and our ability to successfully integrate our new management leadership. Additional factors that could cause our results to differ materially from those described in the forward-looking statements can be found in our recent annual report on Form 10-K, and other reports filed with the Securities and Exchange Commission, and available at the SEC's web site at www.sec.gov. The information set forth herein speaks only as of the date hereof, and except as required by law, we disclaim any intention and does not assume any obligation to update or revise any forward looking statement, whether as a result of new information, future events or otherwise.
Contact:
Diadexus, Inc.
Leone Patterson
Chief Financial Officer
(650) 246-6400
Email Contact
Copyright © 2016 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Did not like Top and Bottom Line in Q.
Names William Hammond As Vice President Of Sales [Market News Publishing (US)]
DIADEXUS INC
DIADEXUS INC ("DDXS-L") - Names William Hammond As Vice President Of Sales
Diadexus, Inc., a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that William Harrison Hammond (Hodi) has joined the Company as Vice President of Sales effective June 22, 2015. Mr. Hammond brings more than 30 years of experience in the medical diagnostics field, including 13 years in various senior and executive roles at Alere and 11 years at Abbott Diagnostics.
"Hodi brings extensive experience in sales and commercial strategy within the diagnostic market, with a deep understanding of the commercial channels," said Lori Rafield, Ph.D., chairman and chief executive officer for Diadexus. "His experience in developing relationships with accountable care organizations and integrated delivery networks will be invaluable as we execute our commercial strategy for our PLAC(r) ELISA and Activity portfolio of products and advance development of our initial heart failure diagnostic biomarker for measuring proADM."
"Diadexus is expanding into the larger hospital market for its PLAC(r) Activity Test while advancing proADM toward the market," said Mr. Hammond. "I look forward to working with the Diadexus team to maximize the commercial potential of the PLAC(r) franchise and prepare for the launch of our first heart failure diagnostic tests."
Most recently, Mr. Hammond was Vice President, Strategic Alliances at Sotera Wireless, an innovator in vital signs monitoring and remote patient surveillance, where he led the effort for contracting health systems, the federal government, and group purchasing organizations. Mr. Hammond previously served as Vice President, Accountable Care Group, at Alere, Inc., where he started and directed the company's efforts to sell all of Alere's diverse products including healthcare technology, POC diagnostics, and home health services designed to manage CHF patients to reduce unnecessary readmissions. Prior positions at Alere include Vice President Sales, Physicians Diagnostics Group, and Vice President, National Accounts. He came to Alere through their acquisition of Biosite where he played a pivotal role in sales and national accounts leadership in developing their POC business. Mr. Hammond previously held sales management positions at Roche Diagnostics, Precision Analytical Laboratories and Abbott Diagnostics. Mr. Hammond holds a B.A. in Economics from Bucknell University.
About Diadexus, Inc.
Diadexus, based in South San Francisco, California, is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. The Company pioneered the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating its utility. Diadexus' products, The PLAC(r) Test ELISA Kit, first cleared by the FDA in 2003, and The PLAC(r) Test for Lp-PLA2 Activity, cleared in December 2014, are the only two FDA-cleared tests to measure Lp-PLA2.
The Company also has a pipeline of biomarkers for heart failure, proADM, proET-1 and proANP, with each providing distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. For more information, please visit the Company's website at www.diadexus.com.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements," including statements regarding, among other things, the impact and the timing of the reverse stock split on the company's business, prospects and/or stock price. Forward-looking statements are based on current expectations and assumptions and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to us that could cause actual results to differ materially from those expressed in such forward-looking statements include the factors necessary to achieve our revenue guidance; sales of our PLAC(r) Test products in the marketplace; our ability to grow revenues from existing and new customers; product pricing and demand with a concentrated customer base; the continued focus of regulatory agencies and payors on costs and our laboratory customer practices; relationships with key customers; our ability to continue to build our heart failure franchise; our ability to identify and build products with additional biomarkers; third party payors' acceptance of and reimbursement for the PLAC(r) Tests; our ability to continue to manufacture the PLAC(r) Tests to meet customer demand; the potential for success of and timing of when our development efforts may be completed; the adequacy of our intellectual property rights and our ability to maintain a proprietary position for our lead product; our limited revenue and cash resources; our significant corporate expenses, including real estate lease liabilities and expenses associated with being a public company; our ability to develop proADM for regulatory submission, and our ability to successfully integrate our new management leadership. Additional factors that could cause our results to differ materially from those described in the forward-looking statements can be found in our most recent annual report on Form 10-K, quarterly report on Form 10-Q, and other reports filed with the Securities and Exchange Commission, and available at the SEC's web site at www.sec.gov. The information set forth herein speaks only as of the date hereof, and except as required by law, we disclaim any intention and does not assume any obligation to update or revise any forward looking statement, whether as a result of new information, future events or otherwise.
Investor Contact: Melissa Forst Argot Partners 212-600-1902
______________________________________
_______________________________________________
OTCBB closing price for DDXS-L Date: 2015/06/30 Closing Price: 0.34
____________________________________________________________
(c)2015 Market News Publishing Inc. All rights reserved.
Toronto:(416)366-8881 Vancouver:(604)689-1101 Fax:(604)689-1106
© (c) 2015 Market News Publishing Inc.
< Back
click here
Our Marketplaces
Market Info
Contact Us
Advertising
Market Hours/Holidays
Corporate Info
About Us
Investor Relations
Press Center
Careers
Sign up for the Newsletter
View Previous Newsletters
Follow Us:
© 2015 OTC Markets Group Inc.Terms of ServiceLinking TermsTrademarksPrivacy StatementRisk WarningSite MapGive FeedbackSupported Browsers? Jump to Top
OTC Link® ATS provided by OTC Link LLC, member FINRA / SIPC, a wholly owned subsidiary of OTC Markets Group Inc.
OTCQX, OTCQB and OTC Pink marketplaces designated by OTC Markets Group.
AdTech Ad
No help so far.......
Need some Real news now.
DDXS one for 15 reverse split:
http://investorshub.advfn.com/boards/manage_msg.asp?message_id=115056493
This must be why the buying volume exploded at the close.
http://www.otcmarkets.com/stock/DDXS/news
Some very nice block buys at the end of the trading session. Maybe,just maybe it will continue upon the open.
Would have liked to see a price Target from them.
Very Nice Subs.. Thank You!
This came out yesterday and its very promising. http://www.wkrb13.com/markets/496786/diadexus-upgraded-to-buy-at-ladenburg-thalmann-ddxs/
As I was hoping After Dec...
GLA.
Hawk
DDXS is on fire! Heavy buying all week to close at .51 :)
Very strong day up 27% with healthy volume & deep bid gaps all afternoon.
JMO...this is a buy low/now and hold through Q1&2 next yr.
Have a strong position now and will patient through then.
GL
Seems like a good company but the trading sucks.. I know many new investors lost money here
ARCA is back up.. Im done here for now. Good luck.. you might wanna try getting Level2 it helps. Later
Everyone is buying.. I can see that from Level2. But the bid is being held back for some reason(ARCA) like i said before. Hopefully it moves before people get tired of buying and start selling.
In light of FDA approval, why not buy at the ASK?
Thats why u don't understand what I'm saying. DDXS had so many buys at .40 but never went up because ARCA was holding shares.. ARCA has now moved to .425 and this will eventually be stuck there. Once ARCA has no more shares this will run.. You will have to get Level 2 to further understand
No...If you mean level2 trading.
Do you have L2??
How must ARCA move. What does it have to do with DDXS P/S?
ARCA is holding this one back big time. This would have been .50+ already.. most likely will move higher tomorrow or whenever ARCA has moved
Someone just Loadd the Boat....JMO
GL in 2015 here...
Q report today.
Going to dial in if time.
GLA.........
Hawk
Insider buys 160k shares @ .50 http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10248499
News on new 15 mil dollar financing
http://online.wsj.com/article/PR-CO-20140818-904366.html
New President to begin on Aug 4th News link below
http://www.marketwatch.com/story/diadexus-announces-leadership-changes-to-drive-and-support-future-growth-potential-2014-06-25
hey dipshit...u buy back in yet ;) My .65's are niiiiice right now
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
419
|
Created
|
12/18/02
|
Type
|
Free
|
Moderators |
diaDexus (DDXS.OB) is a medical diagnostics company, located in South San Francisco, California, focused on the development and commercialization of patent-protected in vitro diagnostic products addressing significant unmet needs in cardiovascular disease.
diaDexus’ first product, the PLAC® Test helps identify individuals at increased risk of suffering a heart attack or stroke, the #1 and #3 causes of death respectively in the U.S. These events can be prevented through early detection and more aggressive risk-reducing strategies.
The PLAC Test measures Lp-PLA2, a vascular-specific inflammatory marker implicated in the formation of rupture-prone plaque, and is the only blood test cleared by the FDA to assess risk for coronary heart disease and ischemic stroke associated with atherosclerosis. There are more than 30 published prospective studies validating Lp-PLA2 as a novel and valuable cardiovascular risk marker that can help improve early risk assessment.
GlaxoSmithKline (GSK) has developed an Lp-PLA2 inhibitor (darapladib) and is currently testing the drug in two large, global, Phase III clinical trials involving over 27,000 patients to determine if inhibition of the enzyme reduces cardiovascular events.
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2011 /PRNewswire/ -- diaDexus, Inc. (OTC Bulletin Board: DDXS), a diagnostics company focused on the development and commercialization of patent-protected in vitro diagnostic products addressing unmet needs in cardiovascular disease, today announced preliminary Q4 2010 revenues of approximately $3.3 million, higher than its prior forecast of $2.8-3.0 million. These preliminary results are unaudited and subject to adjustment prior to the Company filing its Form 10-K on or before March 31, 2011.
The Company also announced a preliminary cash and cash equivalents balance of approximately $20.4 million as of December 31, 2010. This preliminary balance was also higher than the prior Company forecast of $19.7-20.2 million, is unaudited and subject to adjustment prior to the Company filing its Form 10-K on or before March 31, 2011.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |